A Study of Stapokibart Injection in Patients With Atopic Dermatitis (AD)

Recruiting now

Conditions studied: Atopic Dermatitis (AD)

In brief

This study is an open label, prospective study to evaluate the safety and efficacy of Stapokibart Injection in patients with AD.

Key facts

Study ID

NCT07544862

Run by

Chengdu Kangnuoxing Biopharma,Inc.

People needed

1000

Starts

2026-06-02

Expected to finish

2028-02-01

Last updated by the study team

2026-06-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Trial participants aged 18 years or older at baseline, with no restrictions on gender.
• Physician decision to treat trial participants with Stapokibart Injection for AD (according to the China-specific prescribing information) made prior to and independently of the participant's participation in the study.

You may not qualify if…

• Known history of allergic reaction to Stapokibart Injection.
• Trial participants currently or plan participating in any interventional clinical trial.
• Trial participants with hematologic malignancies.
• Women with pregnant.
• Any condition that, in the opinion of the investigator, may interfere with trial participants' ability to participate in the study.

Where it is running

• Peking University People's Hospital — Beijing, Beijing Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.